Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma
- 1 June 2007
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 60 (6), 664-669
- https://doi.org/10.1136/jcp.2006.038331
Abstract
Aim: To study the role of gene promoter hypermethylation of the putative tumour suppressor genes involved in the death-associated protein (DAP) kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma (MM). Method: DNAs from 55 primary MM marrow samples and myeloma cell lines were analysed for aberrant promoter methylation of DAP kinase, p14 and Apaf-1 genes by methylation-specific polymerase chain reaction (MSP). Result: In the methylated positive control, the sensitivity of M-MSP for DAP kinase was 1×10−3. Aberrant hypermethylation of DAP kinase was found in 29/55 (52.7%) primary MM samples, whereas hypermethylation of p14 or Apaf-1 was undetectable in any of the samples tested. 5-Azacytidine treatment of two myeloma cell lines, WL2 and HS-Sultan, led to de-methylation and re-expression of DAP kinase, thereby confirming gene silencing associated with promoter hypermethylation. Hypermethylation of DAP kinase did not correlate with age, sex, paraprotein subtype or Durie–Salmon stage, but negatively affected the overall survival. Conclusion: Of the putative tumour suppressor genes in the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway, only DAP kinase is frequently methylated in MM, which is associated with gene silencing and might be of prognostic significance. p14 and Apaf-1 were not methylated in MM.Keywords
This publication has 30 references indexed in Scilit:
- Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myelomaJournal of Clinical Pathology, 2007
- Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myelomaLeukemia, 2005
- Intrinsic tumour suppressionNature, 2004
- Advances in biology of multiple myeloma: clinical applicationsBlood, 2004
- SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathwayBlood, 2004
- TP53 in hematological cancer: Low incidence of mutations with significant clinical relevanceHuman Mutation, 2003
- Expression of p16INK4A and p14ARF in hematological malignanciesLeukemia, 1999
- P53 deletion is not a frequent event in multiple myelomaBritish Journal of Haematology, 1999
- Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies.1999
- Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cellsLeukemia, 1998